<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005299</url>
  </required_header>
  <id_info>
    <org_study_id>2021.238</org_study_id>
    <nct_id>NCT05005299</nct_id>
  </id_info>
  <brief_title>Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation</brief_title>
  <acronym>VICTORY</acronym>
  <official_title>The VICTORY Study: A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melbourne Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, single center study of short-course oral venetoclax therapy&#xD;
      prior to non-myeloablative conditioning with fludarabine and cyclophosphamide in subjects&#xD;
      with haematological malignancies who are planned for allogeneic stem cell transplantation&#xD;
      (alloSCT). The primary study objective is to determine the safety and maximum tolerated dose&#xD;
      of venetoclax when used in combination with fludarabine and cyclophosphamide conditioning.&#xD;
      Secondary objectives were to evaluate the transplant outcomes and donor/recipient engraftment&#xD;
      of this regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients are to be enrolled sequentially into one of 4 treatment Dose Levels&#xD;
      (beginning with Dose Level A) to receive short-course venetoclax on day -11 to -6, followed&#xD;
      by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide&#xD;
      750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0. In the&#xD;
      dose-escalation phase of this 3+3 study, three patients are planned for each Dose Level.&#xD;
&#xD;
      Dose Level A: venetoclax 100mg daily administered on day -11 to -6 (total venetoclax dose:&#xD;
      600mg)&#xD;
&#xD;
      Dose Level B: venetoclax 100mg daily administered on day -11, followed by 200mg daily&#xD;
      administered on day -10 to -6 (total venetoclax dose: 1100mg)&#xD;
&#xD;
      Dose Level C: venetoclax 100mg daily administered on day -11, followed by 200mg daily&#xD;
      administered on day -10, 400mg daily administered on day -9 and 600mg daily administered on&#xD;
      day -8 to -6 (total venetoclax dose: 2500mg)&#xD;
&#xD;
      Protocol-specific dose-limiting toxicitues (DLTs) will be assessed from the first dose of&#xD;
      venetoclax up to day 30 post-transplant. Subjects will not be treated in a new cohort until&#xD;
      all subjects in the previous cohort had completed the DLT evaluation period and ≤ 1 of 6&#xD;
      subjects had experienced a DLT. If ≥ 2 of 6 subjects experienced a DLT at Dose Level C,&#xD;
      subjects will be treated at Dose B' as part of the dose-escalation phase of this study.&#xD;
&#xD;
      Dose Level B': venetoclax 100mg daily administered on day -11, followed by 200mg daily&#xD;
      administered on day -10 and 400mg daily administered on day -9 to -6 (total venetoclax dose:&#xD;
      1900mg)&#xD;
&#xD;
      The maximum tolerated dose (MTD) is defined as the highest Dose Level at which ≤ 1 of 6&#xD;
      subjects had experienced a DLT. The dose-expansion phase involves recruitment of up to 12&#xD;
      patients at the MTD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2022</start_date>
  <completion_date type="Anticipated">January 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1 study, 3+3 design with dose expansion phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The development of any dose-limiting toxicities</measure>
    <time_frame>Time point between time of first dose of venetoclax to day 30 post-alloSCT</time_frame>
    <description>Dose-limiting toxicities (DLT), defined as any of the following which cannot be clearly attributed to a concurrent illness, concomitant medication or those expected as part of standard allogeneic stem cell transplant (alloSCT) complications:&#xD;
Any grade 3-4 non-haematological adverse events between day -11 to day -1&#xD;
Primary failure of neutrophil engraftment by day 30 post-alloSCT. The date of neutrophil engraftment is defined as the first of 3 consecutive days of neutrophil count ≥ 0.5 x 10^9/L.&#xD;
Primary failure of platelet engraftment by day 30 post-alloSCT. The date of platelet engraftment is defined as the first day of platelet count ≥ 20 x 10^9/L, with no transfusions for at least 7 days prior.&#xD;
Grade 3-4 acute graft-versus-host disease (GVHD) prior to day 30 post-alloSCT&#xD;
Development of Clinical Tumour Lysis Syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute GVHD incidence and severity</measure>
    <time_frame>180 days post allo-SCT</time_frame>
    <description>Acute GVHD (grade 1-4 and grade 3-4) is classified according to the Przepiorka criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD incidence and severity</measure>
    <time_frame>1-year post-alloSCT</time_frame>
    <description>Chronic GVHD (mild, moderate or severe) is classified according to the Filipovich criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD, relapse-free survival (GRFS) incidence</measure>
    <time_frame>1-year post-alloSCT</time_frame>
    <description>GRFS is defined as freedom from grade 3-4 acute GVHD, systemic therapy-requiring chronic GVHD, relapse or death in the first year following alloSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse and non-relapse mortality incidence</measure>
    <time_frame>1-year post-alloSCT</time_frame>
    <description>Relapse is defined as recurrence of disease, determined by radiological or histological grounds.&#xD;
Non-relapse mortality is defined as all-cause mortality without recurrence or progressive disease following alloSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor/recipient chimerism</measure>
    <time_frame>Measured at days 30, 60, 100, 1 year and 2 years following alloSCT</time_frame>
    <description>Myeloid and T-cell chimerism by fragment analysis and capillary electrophoresis of shor tandem repeat markers.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Lymphoblastic, Acute, L1</condition>
  <condition>Leukemia, Lymphoblastic, Acute, L2</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Dose Level A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11 to -6 (total venetoclax dose: 600mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 to -6 (total venetoclax dose: 1100mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10, 400mg daily administered on day -9 and 600mg daily administered on day -8 to -6 (total venetoclax dose: 2500mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level B'</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 and 400mg daily administered on day -9 to -6 (total venetoclax dose: 1900mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax is administered as an oral tablet once daily.</description>
    <arm_group_label>Dose Level A</arm_group_label>
    <arm_group_label>Dose Level B</arm_group_label>
    <arm_group_label>Dose Level B'</arm_group_label>
    <arm_group_label>Dose Level C</arm_group_label>
    <other_name>Venclaxta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.</description>
    <arm_group_label>Dose Level A</arm_group_label>
    <arm_group_label>Dose Level B</arm_group_label>
    <arm_group_label>Dose Level B'</arm_group_label>
    <arm_group_label>Dose Level C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.</description>
    <arm_group_label>Dose Level A</arm_group_label>
    <arm_group_label>Dose Level B</arm_group_label>
    <arm_group_label>Dose Level B'</arm_group_label>
    <arm_group_label>Dose Level C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients are eligible for inclusion if all of the following criteria are met:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Planned to undergo alloSCT for one of the following haematological malignancies: acute&#xD;
             leukaemia (including myeloid and/or lymphoid lineage or biphenotypic), myelodysplastic&#xD;
             syndrome, chronic lymphocytic leukaemia (CLL), B-cell non-Hodgkin lymphoma (NHL) and&#xD;
             plasma cell myeloma&#xD;
&#xD;
          -  Physician preference for a non-myeloablative conditioning regimen&#xD;
&#xD;
          -  Available 10/10 HLA-matched related or unrelated haematopoietic stem cell donor&#xD;
&#xD;
          -  Transplantation to be performed from a peripheral blood stem cell source&#xD;
&#xD;
          -  Adequate renal and hepatic function at screening as follows:&#xD;
&#xD;
               1. Calculated creatinine clearance &gt;50ml/min as measured by Cockroft Gault formula&#xD;
&#xD;
               2. AST and ALT ≤ 3.0 x ULN&#xD;
&#xD;
               3. Bilirubin ≤ 1.5 x ULN (except patients with Gilbert's Syndrome)&#xD;
&#xD;
          -  Able to tolerate oral medications&#xD;
&#xD;
          -  Disease status at the time of transplantation as follows:&#xD;
&#xD;
               1. Acute leukaemia in complete morphologic remission&#xD;
&#xD;
               2. Myelodysplastic syndrome with less than 10% bone marrow blasts&#xD;
&#xD;
               3. CLL in complete remission (CR), partial response (PR) or PR with lymphocytosis&#xD;
&#xD;
               4. NHL in CR or PR&#xD;
&#xD;
               5. Myeloma in CR, very good partial response (VGPR) or PR within 3 months of prior&#xD;
                  autologous stem cell transplantation as part of a tandem auto-allo transplant&#xD;
                  approach&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from this study if any of the following criteria are met:&#xD;
&#xD;
          -  Moderate or high risk of tumour lysis syndrome prior to conditioning for allogeneic&#xD;
             transplantation, defined as:&#xD;
&#xD;
               1. For CLL: Diameter of any lymph node or tumour mass &gt;5cm OR absolute lymphocyte&#xD;
                  count≥25x10^9/L&#xD;
&#xD;
               2. For NHL: Diameter of any lymph node or tumour mass &gt;5cm&#xD;
&#xD;
          -  Prior intolerance of venetoclax or another BCL-2 inhibitor with the exception of&#xD;
             cytopenias. Patients with prior clinical tumour lysis syndrome following venetoclax or&#xD;
             other BCL-2 inhibitor will be excluded from the study if at the time of prior TLS&#xD;
             their disease burden was as follows:&#xD;
&#xD;
               1. For CLL: Diameter of any lymph node or tumour mass &lt;5cm OR absolute lymphocyte&#xD;
                  count≤25x10^9/L&#xD;
&#xD;
               2. For NHL: Diameter of any lymph node or tumour mass &lt;5cm&#xD;
&#xD;
          -  Reticulin fibrosis of the marrow of grade MF 2-3&#xD;
&#xD;
          -  Prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  Haemopoietic cell transplantation - comorbidity index (HCT-CI) score &gt; 5&#xD;
&#xD;
          -  Any currently active malignancy other than the primary indication for alloSCT (except&#xD;
             localized basal cell carcinoma or squamous cell carcinoma of the skin)&#xD;
&#xD;
          -  Uncontrolled systemic infection&#xD;
&#xD;
          -  Known malabsorption syndrome&#xD;
&#xD;
          -  Has received within 7 days prior to the first dose of venetoclax CYP3A4 inducers such&#xD;
             as rifampicin, carbamazepine, phenytoin and St John's wort&#xD;
&#xD;
          -  Has received within 7 days prior to the first dose of venetoclax CYP3A4 inhibitors&#xD;
&#xD;
          -  Known positivity to HIV&#xD;
&#xD;
          -  Significant physical or psychiatric comorbid illness that in the investigator's&#xD;
             opinion would impair the patient's ability to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ritchie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Ritchie</last_name>
    <phone>+61393427000</phone>
    <email>David.Ritchie@mh.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Melbourne Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>David Ritchie, MBBS, PhD</last_name>
      <phone>+61393427000</phone>
      <email>David.Ritchie@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>David Ritchie, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ray Mun Koo, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Koldej, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Wong, MBBS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venetoclax</keyword>
  <keyword>Reduced intensity conditioning</keyword>
  <keyword>Non-myeloablative conditioning</keyword>
  <keyword>Allogeneic stem cell transplant</keyword>
  <keyword>Acute leukemia</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Plasma Cell Myeloma</keyword>
  <keyword>Graft-versus-host Disease</keyword>
  <keyword>Engraftment</keyword>
  <keyword>Graft-versus-Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

